(TPST) Tempest Therapeutics, Inc. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
Your Shortcut to Market Insight Starts Here
This Tempest Therapeutics, Inc. PESTLE Analysis helps you understand the political, economic, social, technological, legal, and environmental forces shaping the company’s risks and opportunities; this page includes a real preview of the report so you can judge style and depth before buying—purchase the full version to receive the complete, ready-to-use company-specific analysis.
Political factors
FDA IND oversight for 2 Phase 1 oncology assets
Tempest Therapeutics relies on US FDA IND oversight for 2 first-in-human oncology programs, TPST-1495 and TPST-1120. These solid-tumor Phase 1 trials need ongoing safety reports, dose-escalation checks, and protocol compliance, so any FDA delay can push readouts and weaken investor confidence. With 2 assets at this stage, regulatory pace is a direct value driver.
US cancer-policy priority
US cancer policy still puts oncology at the center of federal health spending, with the Cancer Moonshot targeting a 50% cut in the cancer death rate over 25 years. That keeps NCI funding, NIH grants, and FDA review focus tilted toward serious, unmet-need cancers. Tempest Therapeutics can benefit because this policy mix favors innovative oncology drugs and faster clinical development paths.
California life-science policy base
Tempest Therapeutics, Inc. is based in South San Francisco, inside California’s biotech core, where dense lab space, CROs, and trial sites cut hiring and development friction. The tradeoff is cost: California’s corporate income tax is 8.84%, and the state minimum wage is $16.50 an hour in 2025, which can push up R and D and operating spend.
That same cluster still helps Tempest recruit scarce scientific talent fast and tap nearby research networks.
Geopolitical supply-chain exposure
Tempest Therapeutics, Inc. depends on global suppliers for reagents, API, and lab services, so any trade frictions, customs delays, or import limits can slow trial work and raise costs. For a clinical-stage biotech with little inventory buffer, even a short disruption can push study timelines and burn more cash. This risk is highest when critical inputs come from a small set of overseas vendors.
Global sourcing raises delay risk.
Import rules can lift costs fast.
Low inventory makes Tempest Therapeutics, Inc. exposed.
Drug-pricing politics in oncology
US drug-pricing politics are intense in oncology: Medicare, which covers about 66 million people, started negotiating prices for 10 drugs in 2024, with the first lower prices taking effect in 2026, and 15 more drugs were added for 2027. For Tempest Therapeutics, Inc., payer acceptance and scrutiny of cancer pricing will shape any future launch price and access. Early clinical differentiation will matter most if assets reach late stage.
- Medicare price pressure is already real
- Oncology faces the harshest scrutiny
- Differentiation supports pricing power
Tempest Faces Rising FDA, Pricing, and California Cost Pressure
Political risk for Tempest Therapeutics, Inc. is highest in FDA review pace, oncology funding, and US drug pricing. Medicare’s 2024 price negotiation covers 10 drugs, with lower prices starting in 2026, and 15 more drugs added for 2027. California also raises cost pressure with an 8.84% corporate tax and a $16.50 minimum wage in 2025.
| Factor | Latest data | Tempest Therapeutics, Inc. impact |
|---|---|---|
| FDA oversight | 2 IND-stage oncology programs | Trial timing risk |
| Medicare pricing | 10 drugs in 2024; 15 more for 2027 | Future launch pricing pressure |
| California costs | 8.84% tax; $16.50 wage in 2025 | Higher R and D spend |
What is included in the product
Detailed Word Document
Assesses how six macro factors shape Tempest Therapeutics, Inc.’s risks and opportunities across Political, Economic, Social, Technological, Environmental, and Legal dimensions.
Customizable Excel Spreadsheet
A concise Tempest Therapeutics PESTLE snapshot that quickly highlights external risks and opportunities for easier planning and decision-making.
Reference Sources
Provides a concise, traceable sources list linking Tempest Therapeutics’ market, clinical, and financial claims to primary industry reports, datasets, and peer-reviewed benchmarks for fast due diligence.
Economic factors
Clinical-stage cash burn
Tempest Therapeutics, Inc. has no marketed product, so its funding depends on outside capital and periodic equity raises. Phase 1 oncology trials are costly for a company of this size, and that makes cash burn a core economic risk. The main pressure points are runway, financing timing, and dilution if new shares must be issued before data readouts.
High cost of solid tumor trials
Tempest Therapeutics, Inc. faces high solid-tumor trial costs because these studies need specialized sites, biomarker testing, and close patient monitoring. Industry estimates put Phase 1 site start-up at about $50,000-$100,000 per site, while biomarker work can add $200-$1,000 per patient. Costs usually jump again in expansion cohorts, and any delay can lift burn and extend timelines fast.
Biotech funding volatility
Small-cap biotech funding stays cyclical, and Tempest Therapeutics is exposed to that swing. One weak trial readout can cut equity access fast, so the company’s valuation can move sharply with market sentiment. In 2025, investors still favored proven late-stage data over early-risk names, keeping funding terms tight.
Interest-rate environment
Higher rates keep Tempest Therapeutics, Inc.’s cost of capital high, and the Fed’s 4.25%-4.50% target range in 2025 kept financing conditions tight for loss-making biotech. That matters because unprofitable drug developers often need repeated equity raises, and each round gets harder when investors demand lower valuations. For Tempest Therapeutics, Inc., the result is a higher hurdle for follow-on funding and a weaker market for long-duration clinical risk.
- High rates raise dilution risk.
- Biotech appetite stays selective.
- Follow-on financing gets tougher.
Partnering and M and A leverage
Oncology assets are often priced off licensing or M&A, and first-in-human data can swing valuation fast. For Tempest Therapeutics, Inc., clean safety and early efficacy readouts are key to attracting non-dilutive capital, because deal terms usually tighten if the package looks weak.
- Early data drives partner interest.
- Strong Phase 1 signals raise price.
- Weak readouts cut leverage fast.
- Deal terms reflect clinical de-risking.
In 2025, biopharma dealmaking stayed concentrated in oncology, where buyers pay for proof-of-concept more than platform promises.
Tempest’s 2025 survival hinges on costly financing and trial timing
Tempest Therapeutics, Inc. remains a cash-burning, pre-revenue biotech, so 2025 financing terms are the key economic driver. Higher rates kept capital expensive, with the Fed at 4.25%-4.50%, and oncology deal flow stayed selective. Any trial delay can lift burn and force a dilutive raise.
| Factor | 2025 data |
|---|---|
| Fed rate | 4.25%-4.50% |
| Phase 1 site start-up | $50k-$100k |
| Biomarker testing | $200-$1,000/patient |
What You See Is What You Get
Tempest Therapeutics, Inc. PESTLE Analysis
The preview shown here is the exact Tempest Therapeutics PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.
No placeholders or teasers—what you see in this snapshot is the final document you’ll download immediately after checkout.
Sociological factors
Rising cancer burden
Cancer remains a major public-health burden, with about 20 million new cases and 9.7 million deaths worldwide in 2022. Most cancers are solid tumors, so demand for new therapies stays high across large patient pools. For Tempest Therapeutics, Inc., that means it operates in a market with deep unmet need and ongoing clinical demand.
Patient preference for targeted therapy
Patients and oncologists increasingly back therapies with a clear biological story, and Tempest Therapeutics, Inc.'s TPST-1495 and TPST-1120 fit that pull through receptor and pathway targeting. In a market where 1 strong mechanism can lift trial interest and adoption, Tempest Therapeutics, Inc. can use this science-led positioning to stand out in Phase 1/2 development and build trust.
Clinical trial participation barriers
Clinical trial enrollment in oncology is still hard: only about 3% to 5% of adult cancer patients join trials, and access often depends on distance to major centers, referrals, and health status. For Tempest Therapeutics, Inc., that means small patient pools and slower screening can stretch timelines and lift trial costs. In a field where every month delays readouts, enrollment risk can hit cash burn fast.
Demand for better tolerability
Solid-tumor care often means 2+ prior therapy lines, so patients and oncologists favor drugs that add efficacy without harsh toxicity. With about 2,041,910 new U.S. cancer cases expected in 2025, Tempest Therapeutics, Inc. must position early assets around clear benefit-risk and easy combination use.
- 2+ prior lines raise safety demands
- 2025 U.S. cases: 2,041,910
- Better tolerability helps combo uptake
Equity in trial access
Diversity gaps in oncology trials still limit how well safety and efficacy data reflect real patients; Black people are 13.6% of the U.S. population, so Tempest Therapeutics, Inc. needs broader reach to avoid skewed data.
Broader enrollment makes efficacy and safety results more reliable across age, race, and geography. Tempest Therapeutics, Inc. should pick sites near diverse patient pools and use local outreach to lift access.
- Use diverse sites
- Expand local outreach
- Improve data relevance
High Cancer Demand Raises Tempest’s Trial Access and Diversity Risks
Oncology demand stays high, with 2,041,910 U.S. cancer cases expected in 2025 and only 3% to 5% of adults joining trials. For Tempest Therapeutics, Inc., that makes access, referral reach, and site location key social risks. Patients and oncologists also favor tolerable, clear-benefit drugs, and diverse enrollment matters because Black people are 13.6% of the U.S. population.
| Factor | Data |
|---|---|
| 2025 U.S. cancer cases | 2,041,910 |
| Adult trial enrollment | 3%-5% |
| Black share of U.S. population | 13.6% |
Technological factors
Dual EP2 and EP4 inhibition
Tempest Therapeutics, Inc.'s TPST-1495 is built to block both EP2 and EP4, two prostaglandin E2 receptors, in one molecule. That dual hit is meant to lower tumor-driven immune suppression and support T-cell activity, which fits a pathway-based cancer immunology strategy. The design is notable because EP4 and EP2 signaling are both linked to a pro-tumor, immune-evasive microenvironment.
PPAR alpha blockade
TPST-1120 is Tempest Therapeutics, Inc.’s lead small-molecule blocker of peroxisome proliferator-activated receptor alpha (PPARα), a 1-target approach designed to shift tumor metabolism and immune signaling. In oncology, this differentiated mechanism aims to hit both cancer biology and the immune response. That matters because PPARα blockade is a non-checkpoint strategy in a field still dominated by fewer than 10 major immune-drug classes.
TREX-1 biology platform
Tempest Therapeutics, Inc. is also exploring TREX-1, a cellular enzyme that helps control innate immune signaling in cancer, which adds a third discovery lane beyond its 2 clinical candidates. That platform-style approach can widen its target pool and improve optionality if one program stalls. The key point: TREX-1 can support broader pipeline growth without adding a new company.
Biomarker-driven development
Biomarker-driven development is key for Tempest Therapeutics, Inc. because modern oncology trials work best when they find the right patient subgroup early. In biomarker-selected cancer studies, response rates can be far higher than in unselected groups, so early translational signals can lift trial success odds and guide later-stage design. That also helps Tempest avoid spending scarce cash on broad, low-signal studies.
- Find responders early
- Refine later-stage trial design
- Reduce wasted development spend
Small-molecule manufacturing advantage
Tempest Therapeutics, Inc.'s small-molecule focus can be a real manufacturing edge because these drugs are usually easier to scale than biologics, which often need complex cold-chain handling and specialized facilities. Oral dosing can also cut logistics friction and improve patient use, which matters if the science works and Tempest moves toward commercialization. That lower production burden can help protect margins and speed launch planning.
- Small molecules scale more easily.
- Oral dosing can simplify delivery.
- Lower complexity can support margins.
- Commercial upside depends on efficacy.
Tempest’s Small-Molecule Cancer Bet Targets Tumor-Immune Pathways
Tempest Therapeutics, Inc. uses small-molecule oncology tech to block EP2/EP4, PPARα, and TREX-1, so it is betting on tumor-immune and metabolism pathways rather than checkpoint drugs alone. Biomarker-led trial design can lift signal in small studies and cut wasted spend. Oral small molecules also tend to be easier to scale than biologics.
| Tech factor | Implication |
|---|---|
| TPST-1495 | Dual EP2/EP4 block |
| TPST-1120 | PPARα inhibition |
| TREX-1 | Pipeline expansion |
Legal factors
FDA clinical trial compliance
Tempest Therapeutics must keep every clinical program aligned with FDA IND, GCP, and safety-reporting rules, especially in Phase 1 dose-escalation studies where adverse events are watched in real time. In 2025, FDA issued multiple clinical holds across early oncology programs when safety data or protocols were weak, showing how fast noncompliance can delay development or stop a trial.
Patent protection
Patent protection is a key legal risk for Tempest Therapeutics, Inc. because it has just 2 early-stage assets, so every year of exclusivity matters. Tempest needs broad patents on chemical matter, methods of use, and formulations to block fast-follow rivals and support future licensing talks. If its IP is weak, partner value and deal leverage can drop fast.
HIPAA and trial-data privacy
Oncology trials collect highly sensitive health data, so Tempest Therapeutics must enforce HIPAA controls, vendor checks, and tight data-sharing rules. HHS Office for Civil Rights has already issued HIPAA penalties above $2 million in recent cases, showing the cost of weak privacy controls. A breach can trigger fines, trial delays, and lasting reputational damage.
Public-company disclosure duties
Tempest Therapeutics, Inc., as a public biotech, must keep SEC disclosures current, especially on trial data, cash use, and financing. For development-stage firms, even one setback or capital raise can trigger a Form 8-K or amended risk disclosure, and that duty is stricter because data can move fast and shares can swing hard. In 2025, this legal load matters more when the pipeline is still the main value driver.
- Accurate SEC reporting is mandatory
- Clinical news can trigger filings
- Financing updates need fast disclosure
- Volatile data raises legal risk
Product-liability exposure
Tempest Therapeutics, Inc. faces product-liability exposure even in early trials, because serious adverse events can trigger claims, protocol pauses, or regulatory review. With no approved product on sale yet, the main risk sits in clinical testing, where trial insurance, indemnities, and clear informed-consent forms help limit losses.
If either candidate reaches market, liability risk would jump fast, since post-market claims can be much larger and harder to cap. FDA consent rules under 21 CFR 50 make disclosure of known risks a key legal shield.
- Trial-stage risk still matters.
- Insurance and indemnities are essential.
- Commercial liability would rise sharply.
Tempest Faces High Legal and IP Risk Across Trials, Privacy, and Filings
Tempest Therapeutics, Inc. faces high legal risk from FDA trial rules, HIPAA privacy duties, and SEC disclosure demands, because one safety or data lapse can delay programs, trigger fines, or force new filings. Patent strength is also critical, since its value depends on protecting a small, early-stage pipeline.
| Legal factor | Tempest impact |
|---|---|
| FDA/IND | Hold risk |
| HIPAA | Privacy fines |
| SEC | Fast filings |
| IP | Exclusivity |
Environmental factors
Laboratory waste management
Tempest Therapeutics' oncology R&D can create solvent, sharps, and biohazard waste, so disposal controls must be tight. EPA hazardous-waste rules and OSHA bloodborne-pathogen standards raise handling costs, but they also cut injury and compliance risk. For a small biotech with no product revenue yet, even modest waste fees can bite cash burn and lab efficiency.
Energy use in research operations
Biotech labs can use 3 to 5 times more energy than typical offices, with -80°C freezers often drawing about 20 to 25 kWh a day. In California, high power prices make facility efficiency a direct cost issue for Tempest Therapeutics, Inc., especially for ventilation and instrumentation. Better energy management can cut expenses and lower Scope 2 emissions in ESG reporting.
Climate-related supply-chain risk
Climate-related supply-chain risk can hit Tempest Therapeutics, Inc. hard because storms, heat, and floods can delay shipping, disrupt trial sites, and spoil temperature-sensitive samples. The World Meteorological Organization said 2024 was the warmest year on record, and severe weather is now a recurring logistics threat. For a geographically spread clinical program, even short transport delays can create missed visits, sample loss, and higher trial execution costs.
California environmental rules
Tempest Therapeutics, Inc. faces California’s tighter environmental regime, where wet-lab biotech sites must manage chemical storage, waste, air permits, and worker safety under Cal/OSHA and local rules. California also generated 4.5 million tons of hazardous waste in 2024, so compliance for labs can add real cost and time. For a small biotech, even minor permit delays can slow research schedules.
- Strict state rules raise compliance overhead.
- Hazardous waste handling is a key cost.
- Wet-lab operations face the biggest burden.
ESG expectations from investors
Institutional investors now expect clear environmental disclosure, even from small biotechs like Tempest Therapeutics, Inc.; in 2025, global sustainable fund assets were still about $3.2 trillion, showing ESG remains a live capital-market screen. Strong vendor controls, waste and energy policies, and simple reporting can reduce reputational risk and improve access to financing.
- Investors want visible ESG data
- Small biotechs are still judged
- Good ESG can help funding access
Tempest Faces Rising Climate, Energy, and ESG Costs
Tempest Therapeutics, Inc. faces higher lab-waste, energy, and climate-disruption costs as a California wet-lab biotech. EPA/OSHA and state rules raise handling burden, while 2024 was the warmest year on record, lifting trial and logistics risk. Investor ESG screens still matter, with global sustainable fund assets near $3.2 trillion in 2025.
| Factor | Latest data | Impact |
|---|---|---|
| Climate | 2024 warmest year | Trial delays |
| Energy | -80C freezer 20-25 kWh/day | Higher burn |
| ESG capital | $3.2T | Funding screen |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.